Biosimilar User Fee Collections Drop Well Below Estimates, But US FDA Not Worried

 
• By Derrick Gingery
FDA entrance sign 2016
Estimates for PDUFA and GDUFA were much closer to actual cash collections.

More from Biosimilars

More from Biosimilars & Generics